November 2009- Volume 5, Issue 11
November 2009
In this Issue
Feature
Publisher's note: 'Tis the season to reflect on the year's blessings
Publisher's note: 'Tis the season to reflect on the year's blessings
ddn blessed with continued growth and expansion this Thanksgiving
Informatics
Kendle adds OmniComm’s TrialMaster EDC solution to e-clinical offerings
Kendle adds OmniComm’s TrialMaster EDC solution to e-clinical offerings
Leading global CRO Kendle announced in October that it will add OmniComm’s TrialMaster EDC solution to its current e-clinical offerings in a multi-year enterprise-wide agreement.
Unity in sequencing
Unity in sequencing
CLC bio scores two collaboration deals integrating its technology with that of BIOBASE and GenoLogics
BioClinica adds another piece to the pie
BioClinica adds another piece to the pie
Company acquires supply chain simulation and parameter-driven interactive voice and web response technology (IXR) developer Tortellotte to add to its e-clinical services
Playing in Europe now
Playing in Europe now
Phase Forward inks multi-year data management agreement with European pharma Gedeon Richter
Australian researchers: G'day, pathways
Australian researchers: G'day, pathways
QFAB selects Ingenuity Systems' IPA in multiyear deal for systems biology effort
Automation & Instrumentation
MPI imaging technology aims at human application
MPI imaging technology aims at human application
Philips and Bruker BioSpin to develop new magnetic particle imaging scanners for the preclinical market
Where the hardware meets wetware
Where the hardware meets wetware
Enzo Biochem and BioTek Instruments collaborate on development of system for the study of live cells
Arrestin developments
Arrestin developments
DiscoveRx signs worldwide agreement to provide GSK with access to PathHunter _-Arrestin cell lines and reagents for GPCR screening
Amped-up MDx assays
Amped-up MDx assays
Quidel, BioHelix in deal to develop in vitro molecular diagnostic tests
New Products
Membrane adsorber for hydrophobic interaction chromatography
Membrane adsorber for hydrophobic interaction chromatography
Sartorius Stedim Biotech has launched the first commercially available membrane adsorber for hydrophobic interaction chromatography (HIC). Sartobind Phenyl membrane adsorbers allow increased flow rates to ensure faster processes and can be used for process upgrades in purification and polishing of therapeutic proteins.
Fast, efficient and competitive pipetting
Fast, efficient and competitive pipetting
CyBi-SELMA is a semi-automatic pipettor that is fast, precise and robust. With 96 disposable tips, all 96- and 384-well microplate formats can be filled in seconds.
System combines top-down and bottom-up proteomics to improve biomarker discovery
System combines top-down and bottom-up proteomics to improve biomarker discovery
Bio-Rad Laboratories Inc. and Bruker Corp. have jointly launched the Lucid Proteomics System, the first system to combine top-down and bottom-up proteomics approaches for biomarker discovery.
Genomics & Proteomics
A good match for sequencing
A good match for sequencing
Life Technologies and febit team up to provide resequencing products and services
Right on target
Right on target
Roche and SAIC-Frederick partner on targeted resequencing of cancer genes
The pathway less traveled
The pathway less traveled
TGen, Scottsdale Healthcare researchers use computer simulations to validate treatment targets for lung cancer
Study and re-study
Study and re-study
Wayne State, U of Michigan partner with Toronto hospital on childhood OCD research
Big Blue goes after holy grail
Big Blue goes after holy grail
IBM aims to achieve the $1,000 genome goal by running DNA through its computer chip-like DNA Transistor
Global News
Big Pharma under fire
Big Pharma under fire
European regulators raid top pharmas for suspected antitrust activity
A blossoming diagnostic duo
A blossoming diagnostic duo
Qiagen acquires DxS in deal worth up to $130 million
Bitten by the ‘kissing bug’
Bitten by the ‘kissing bug’
Eisai and DNDi to collaborate on a new drug for Chagas disease
Swiss companies aiming for peptide pinnacle
Swiss companies aiming for peptide pinnacle
mondoBIOTECH and Bachem sign long-term deal aimed at fighting rare diseases
sanofi-aventis sees eye-catching deal
sanofi-aventis sees eye-catching deal
French pharma acquires ophthalmology-focused Fovea Pharmaceuticals for $543 million
Research & Development
Taking a stake
Taking a stake
Johnson & Johnson invests $444 million in Crucell to develop therapies for influenza and other diseases
Total knockout of Parkinson's
Total knockout of Parkinson's
Michael J. Fox Foundation, Sigma-Aldrich researchers count on knockout rats to deliver a KO punch to Parkinson's disease
Gen-Probe spreads infectious disease reach
Gen-Probe spreads infectious disease reach
Company agrees to acquire molecular testing company Prodesse in $60 million cash deal, plus more in milestones
Oncology research hits the Outback
Oncology research hits the Outback
Australia’s Cancer Therapeutics collaborates with Duke University to develop cancer drug therapies
Benefiting from BPM
Benefiting from BPM
Savvion-Patni Life Sciences CRO partnership focuses on delivering business process management-enabled services
Commentary
Warning: Out of focus and multitasking
Warning: Out of focus and multitasking
Focus is my favorite business word and my most challenging objective. We know from established science that multitasking doesn't work. It is dangerous in moving vehicles and not too effective in classrooms, business or government.
Translating between preclinical data and clinical outcomes: The bottleneck is always on the other side
Translating between preclinical data and clinical outcomes: The bottleneck is always on the other side
You can have the best tools possible, but if you don’t have the skills to use them—or don’t fully understand the question at hand—there will always be a bottleneck on one side or another.
Editor's Focus
On your mark, get set … the race for the $1,000 genome heats up
On your mark, get set … the race for the $1,000 genome heats up
Who will be the first to cross the finish line in the race to achieve the $1,000 genome? Our cover story details how the latest entrant in this quest, IBM, is developing a technology that the computer technology giant believes could put it in front of the international race to drive down the cost of gene sequencing.
